Not medical advice. This website is not medical advice, a diagnosis, a match to a trial, or a recommendation to join a study. Listings are plain-English rewrites of public ClinicalTrials.gov records. Whether a site is still enrolling, and whether you qualify, can only be confirmed by the study team and your clinician. Source registry: ClinicalTrials.gov. Editorial rules: methodology.
PlainTrials
RecruitingPhase 4interventionalRules rewrite

Phase 4: testing Dupilumab for Asthma

Single center, randomly assigned, dummy treatment (placebo)- controlled study to assess change in mucociliary clearance of moderate to severe asthma patients after treatment with dupilumab or dummy treatment (placebo).

Official registry: https://clinicaltrials.gov/study/NCT04743791 · Sally E. Wenzel MD · enrollment listed as 30

What this phase means

Phase 4: the treatment is already approved. This study asks new questions — longer-term effects, other diseases, or how it compares in everyday care.

Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.

What the registry says happens

If you join, the listed intervention(s) are Dupilumab, or Placebo. The registry lists allocation as randomized. Single center, randomly assigned, dummy treatment (placebo)- controlled study to assess change in mucociliary clearance of moderate to severe asthma patients after treatment with dupilumab or dummy treatment (placebo).

They plan to enroll about 30 people at Pittsburgh. Taking part typically means taking a study drug (or dummy pill) plus check-ins.

Official title (unrewritten)

A Randomized, Placebo-controlled, Parallel Group Study Designed to Assess the Change in Mucociliary Clearance After 12 Weeks of Treatment With Dupilumab in Patients With Moderate to Severe Asthma

Interventions: Dupilumab, Placebo

Primary outcome (registry wording): Change in mucociliary clearance (MCC) rate

Who it is for (from inclusion criteria)

  • Ages 18 Years to any
  • Moderate - Severe Th2 (Type 2) High asthma, as defined by Forced Expiratory Volume in one second (FEV1) \<90% predicted, on medium to high dose inhaled corticosteroids (ICS) with or without a second controller
  • Inhaled steroid doses of 500micrograms (mcg) per day or more (Fluticasone equivalent)
  • Reversibility \>/= 12% at screening or within the past 2 years, or a positive methacholine challenge test within the past 2 years, or a positive methacholine challenge during screening
  • FEV1/Forced Vital Capacity (FVC)\<75%
  • Blood Eosinophils (EOS) \>300 cells per mm3
  • Exhaled Nitric Oxide (FeNO) \>25 parts per billion (ppb)
  • Asthma Control Test (ACT) score \<20

Public study contact (from the registry)

John Moore

412-648-6726

mooreja6@upmc.edu

Published on ClinicalTrials.gov. Contact them as a possible participant. They decide eligibility.

Sites listed on ClinicalTrials.gov

1 listed

Related recruiting trials in this snapshot

RecruitingNot a traditional drug phaseBethesda, Maryland
Role of Genetic Factors in the Development of Lung Disease

This study is designed to measure the genetics involved in the development of lung disease by surveying genes involved in the process of breathing and examining the genes in lung cells of patients with lung disease. The study will focus on defining the distribution of abnormal genes responsible for processes directly involved in different diseases affecting the lungs of patients and healthy volunteers.

NCT00001532 · Official ClinicalTrials.gov record · National Heart, Lung, and Blood Institute (NHLBI)

FAQ about this NCT record

Is NCT04743791 still recruiting?

The sponsor posted status “Recruiting” on ClinicalTrials.gov at last ingest. Sites can pause independently. Confirm with the official record and the listed contact.

What phase is NCT04743791?

Phase 4. Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.

Can PlainTrials tell me if I qualify for NCT04743791?

No. The inclusion and exclusion lists on this page are readable extracts of the public eligibility block. Only the study team can screen you.

How to read a ClinicalTrials.gov record · Questions to ask the coordinator · Glossary